European Union: Boost for AIDS Pill
January 31, 2008
Illinois-based Abbott Laboratories reports it has won a European regulatory advisory committee's endorsement of the pediatric formulation of its AIDS drug Kaletra. The approval means the child-size dose could be available for sale in Europe in 60 to 90 days. European clearance of a drug typically leads to approval in developing nations as well. Kaletra is known in some countries as Aluvia.
01.31.2008; Bruce Japsen
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.